Mimedx (MDXG) Assets Average (2011 - 2026)
Mimedx recorded quarterly Assets Average of $325.7 million in Q1 2026, down 1.56% quarter-over-quarter from $330.8 million in Q4 2025, and up 21.9% year-over-year from $267.2 million in Q1 2025.
Mimedx's Assets Average history runs 15 years deep, the most recent figure standing at $325.7 million for Q1 2026.
- In Q1 2026, Assets Average rose 21.9% year-over-year to $325.7 million; the TTM figure through Mar 2026 stood at $325.7 million (up 21.9% YoY), while the FY2025 annual figure was $303.3 million, up 20.6% from the prior year.
- Assets Average came in at $325.7 million for Q1 2026 at Mimedx, down from $330.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $330.8 million in Q4 2025 to a low of $169.8 million in Q1 2023.
- A 5-year average of $228.9 million and a median of $225.9 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average fell 9.22% in 2022 and jumped 35.67% in 2024, its largest moves.
- Mimedx's Assets Average stood at $172.1 million in 2022, then rose by 24.36% to $214.0 million in 2023, then increased by 18.63% to $253.9 million in 2024, then surged by 30.29% to $330.8 million in 2025, then dropped by 1.56% to $325.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $325.7 million, $330.8 million, and $305.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 325.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 325.66 Mn |
| Dec 31, 2025 | 330.82 Mn |
| Sep 30, 2025 | 305.05 Mn |
| Jun 30, 2025 | 280.76 Mn |
| Mar 31, 2025 | 267.17 Mn |
| Dec 31, 2024 | 253.90 Mn |
| Sep 30, 2024 | 237.04 Mn |
| Jun 30, 2024 | 225.93 Mn |
| Mar 31, 2024 | 230.36 Mn |
| Dec 31, 2023 | 214.03 Mn |
| Sep 30, 2023 | 182.70 Mn |
| Jun 30, 2023 | 172.27 Mn |
| Mar 31, 2023 | 169.79 Mn |
| Dec 31, 2022 | 172.11 Mn |
| Sep 30, 2022 | 170.73 Mn |
| Jun 30, 2022 | 171.56 Mn |
| Mar 31, 2022 | 181.19 Mn |
| Dec 31, 2021 | 184.23 Mn |
| Sep 30, 2021 | 183.84 Mn |
| Jun 30, 2021 | 188.98 Mn |
| Mar 31, 2021 | 196.42 Mn |
| Dec 31, 2020 | 207.68 Mn |
| Sep 30, 2020 | 182.12 Mn |
| Jun 30, 2020 | 154.91 Mn |
| Mar 31, 2020 | 163.04 Mn |
| Dec 31, 2019 | 173.22 Mn |
| Sep 30, 2019 | 174.79 Mn |
| Jun 30, 2019 | 138.88 Mn |
| Mar 31, 2019 | 115.14 Mn |
| Dec 31, 2017 | 149.98 Mn |
| Sep 30, 2017 | 189.29 Mn |
| Jun 30, 2017 | 194.18 Mn |
| Mar 31, 2017 | 152.88 Mn |
| Dec 31, 2016 | 149.47 Mn |
| Sep 30, 2016 | 179.36 Mn |
| Jun 30, 2016 | 177.14 Mn |
| Mar 31, 2016 | 156.57 Mn |
| Dec 31, 2015 | 130.92 Mn |
| Sep 30, 2015 | 119.88 Mn |
| Jun 30, 2015 | 109.97 Mn |
| Mar 31, 2015 | 107.68 Mn |
| Dec 31, 2014 | 103.29 Mn |
| Sep 30, 2014 | 91.67 Mn |
| Jun 30, 2014 | 86.69 Mn |
| Mar 31, 2014 | 86.02 Mn |
| Dec 31, 2013 | 65.00 Mn |
| Sep 30, 2013 | 42.79 Mn |
| Jun 30, 2013 | 39.07 Mn |
| Mar 31, 2013 | 36.52 Mn |
| Dec 31, 2012 | 34.36 Mn |
| Sep 30, 2012 | 30.50 Mn |
| Jun 30, 2012 | 27.17 Mn |
| Mar 31, 2012 | 26.98 Mn |
| Dec 31, 2011 | 25.32 Mn |
| Sep 30, 2011 | 23.92 Mn |